Management of persistent acromegaly following primary therapy: The current landscape in the UK
Abstract Acromegaly is the clinical consequence of chronic exposure of the tissues to excess GH and IGF‐I. It is almost exclusively the result of a GH‐secreting pituitary adenoma. In addition to the somatic features, uncontrolled acromegaly is associated with a number of complications and excess mor...
Main Authors: | Nikolaos Kyriakakis, Khyatisha Seejore, Ahmed Hanafy, Robert D. Murray |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.158 |
Similar Items
-
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01) -
A Rare Case of McCune-Albright Syndrome in Association with Acromegaly: Treatment Options and a Review of the Literature
by: Hande Peynirci, et al.
Published: (2022-12-01) -
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
by: Lingyun Ma, et al.
Published: (2020-08-01) -
Acromegaly: Beyond surgery
by: Gaya Thanabalasingham, et al.
Published: (2013-01-01) -
The position of combined medical treatment in acromegaly
by: Eva C. Coopmans, et al.
Published: (2020-01-01)